Trial
NCT00795639
Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)
Phase IIITERMINATEDSAFETYConfidence: HIGH
Sponsor
Pfizer
Collaborators
—
Condition
Pulmonary Arterial Hypertension
Intervention
Sitaxsentan
Why stopped
Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-03-24